Peppermint Oil for IBS: Evidence and Safety

Peppermint oil is a concentrated preparation from the peppermint plant. The main IBS research concerns capsules designed to release their contents beyond the stomach. Research on peppermint leaf is much more limited, and different ways of using peppermint answer different questions.^{See reference 1}

Check whether a claim refers to an enteric-coated capsule, another release formulation or a combination product. A mint flavour, a plant name and an oil amount do not by themselves establish equivalence to the product tested in a trial.^{See reference 1,See reference 3}

The 2022 review estimated a relative risk of remaining unimproved of 0.65 for overall IBS symptoms, with a 95% confidence interval of 0.43 to 0.98. That is not a claim that 65% of people improve or that everyone has the same chance of benefit. The authors rated the evidence very low in certainty.^{See reference 2}

The 2020 trial illustrates why endpoint choice matters. Its prespecified primary outcomes were not clearly better than placebo, even though some secondary scores improved with small-intestinal release. Reporting only those favourable secondary findings would exaggerate the result.^{See reference 3}

The 2021 trial studied enteric-coated peppermint oil at 180 mg three times daily for six weeks. Its results did not establish an advantage over placebo. A tested amount is therefore not automatically a proven effective dose, and it is not a recommendation to start or increase treatment.^{See reference 4}

The 2020 trial compared 182 mg preparations with different release locations for eight weeks. Those details help identify the research intervention; they do not show that a different over-the-counter formulation is interchangeable.^{See reference 3}

A 2026 trial randomized 228 children aged 8 to 18 with IBS or functional abdominal pain to peppermint oil capsules, peppermint sweets or placebo for eight weeks. Neither active approach was superior to placebo for the study’s treatment-success outcome. Adverse events were reported as mild and infrequent.^{See reference 5}

This was a distinct paediatric population. It should not be used to erase every adult finding, but the adult evidence also cannot justify assuming a child will benefit. The trial’s capsule and sweet formulations are not a home-treatment recipe.^{See reference 5}

Oral peppermint oil can cause heartburn, nausea, abdominal pain and dry mouth; allergic reactions are possible. Enteric coating may reduce heartburn, but it does not eliminate every side effect. Evidence about medicinal amounts during pregnancy or breastfeeding is limited.^{See reference 1}

The NHS notes that indigestion medicines, including antacids and acid-suppressing medicines, can affect peppermint oil capsule use. Ask a pharmacist to check the exact formulation, its leaflet and your medicine list. Do not stop a prescribed medicine or invent a timing schedule from a general supplement guide.^{See reference 6}

Concentrated essential oils should not be treated as food or assumed suitable for swallowing. Keep product form, route and age warnings clear. NCCIH specifically warns against inhaling menthol or applying it to the face of an infant or small child because of breathing risks.^{See reference 1}

Identify the full product, oil amount, release formulation, other active ingredients and manufacturer instructions. Independent quality testing can help check aspects of product identity or contamination, but it does not prove the product treats IBS or make it suitable for a particular person.^{See reference 7}

A symptom claim should identify the population and evidence it refers to. “Digestive support” alone does not tell you whether a product was tested for IBS, indigestion, nausea or something else. Those are different outcomes.^{See reference 1,See reference 3}